BeOne Medicines
Tracked across 4 events · 24 articles · First seen Apr 13, 2026 · Last active Jun 30, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: BeOne Medicines received the 'Outstanding Global Oncology Company of the Year' award, recognizing its advancements in R&D and manufacturing of cancer therapies, which positively impacts its reputation and market standing.
May 11, 2026 · 6 articles
Tech
Impact: BeOne Medicines announced positive topline results from its Phase 3 MANGROVE study for Zanubrutinib, which is expected to significantly boost its market position and future revenue in oncology.
Jun 30, 2026 · 6 articles
Tech
Impact: BeOne Medicines provided Tislelizumab under a clinical drug supply agreement for AnBogen Therapeutics's Phase 1/2 clinical trial.
Apr 13, 2026 · 6 articles
Business
Impact: Dr. Michelle Mellion previously held a Chief Medical Officer role at BeOne Medicines, leading clinical development efforts.
May 12, 2026 · 6 articles
100
BeOne Medicines announced positive resultsBeOne BRUKINSA Phase 3 Success
80
BeOne Medicines planned regulatory submissionsBeOne BRUKINSA Phase 3 Success
ERGEN INTELLIGENCE
Track BeOne Medicines live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard